Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, open-label Phase 1/2 neoadjuvant clinical trial of EGL-001 in patients with head and neck squamous cell carcinoma (HNSCC)

Next Previous
Trial Profile

A multicenter, randomized, open-label Phase 1/2 neoadjuvant clinical trial of EGL-001 in patients with head and neck squamous cell carcinoma (HNSCC)

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 11 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EGL 001 (Primary) ; Pembrolizumab (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 11 Mar 2026 New trial record
  • 02 Mar 2026 According to Egle Therapeutics media release, company announced that it was awarded approximately 8 million in grant funding by Horizon Europe, the European Commissions key funding program for research and innovation. This funding from the European Union will support an Egle-led initiative in partnership with a consortium of four leading European scientific institutions to advance the clinical development of EGL-001.
  • 02 Mar 2026 According to Egle Therapeutics media release, company will collaborate with University College London (United Kingdom), Vall dHebron Institute of Oncology (VHIO) (Spain), Gustave Roussy (France), and Technical University of Dresden (Germany) to conduct this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top